公开(公告)号：CA2096709C

公开(公告)日：2005-04-19

申请号：CA2096709

申请日：1993-05-20

Applicant: HOECHST AG

Inventor： KRASS NORBERT ,  DEFOSSA ELISABETH ,  FISCHER GERD ,  GERLACH UWE ,  HORLEIN ROLF ,  LATTRELL RUDOLF ,  LINKIES ADOLF H ,  MARTIN WOLFGANG ,  STACHE ULRICH ,  WOLLMANN THEODOR

IPC: C07D501/00 ,  C07D501/04 ,  C07D501/18

Abstract: The present invention relates to a process for the preparation of 7-amino-3-methoxymethylceph-3-em-4-carboxylic acid (I) from 7-amino-3-methoxymethylceph-3-em-4-carboxylic acid esters (II) or their salts by ester cleavage. The process comprises treating the compound II with formic acid, trifluoroacetic acid, methanesulfonic acid or trifluoromethanesulfonic acid or a mixture of two of these acids in each case.

公开(公告)号：CA2069200C

公开(公告)日：2004-01-27

申请号：CA2069200

申请日：1992-05-22

Applicant: HOECHST AG

Inventor： DEFOSSA ELISABETH ,  FISCHER GERD ,  JENDRALLA JOACHIM-HEINER ,  LATTRELL RUDOLF ,  WOLLMANN THEODOR ,  ISERT DIETER

IPC: A61K31/545 ,  A61K31/546 ,  A61P31/04 ,  C07B57/00 ,  C07D417/12 ,  C07D501/00 ,  C07D501/12 ,  C07D501/18 ,  C07D501/32 ,  C07D501/34

Abstract: The invention relates to crystalline acid addition salt of the two diastereomers of the 1-(2,2-dimethylpropionyl- oxy)-ethyl- 3-cephem-4-carboxylate of the general formula II (see formula I) in which X is the anion of a physiologically acceptable, mono- or polybasic, inorganic or organic acid and the group =N-OH is in the syn-position, pharmaceutical formulations which are active against bacterial infec- tions and contain such cephem derivatives, processes for the preparation of the cephem derivatives and the use of the cephem derivatives for combating bacterial infections.

公开(公告)号：FI108725B

公开(公告)日：2002-03-15

申请号：FI923966

申请日：1992-09-04

Applicant: HOECHST AG

Inventor： FICSHER GERD ,  DEFOSSA ELISABETH ,  GERLACH UWE ,  HOERLEIN ROLF ,  KRASS NORBERT ,  LATTRELL RUDOLF ,  STACHE ULRICH ,  WOLLMANN THEODOR ,  ISERT DIETER

IPC: A61K31/545 ,  A61K31/546 ,  A61P31/04 ,  C07D501/00 ,  C07D501/06 ,  C07D501/34 ,  C07D501/56

Abstract: Enterally absorbable diastereomers of (6R,7R)-7-[2-(2-aminothiazol-4-yl)-2-(Z)-(methoxyimino)acetamido]-3-(m ethoxymethyl)-3-cephem-4-carboxylic acid 1-(isopropoxycarbonyloxy)ethyl ester of the formula I and its physiologically acceptable salts and also diastereomerically pure salts of the compounds of the general formula II where HX represents a mono- or polybasic acid and where X represents an inorganic or organic physiologically acceptable anion, and a process for the preparation of these compounds of the formula I or II are described, which is characterised in that on mixing together one equivalent of a solution of the diastereomer mixture of the formula III with 0.2 - 2 equivalents of a solution of the acid component HY the more poorly soluble diastereomer of the general formula IV is first precipitated and separated off by filtration, then the more readily soluble diastereomer of the general formula IV is precipitated from the filtration solution, it being possible in the subsequent subsidiary steps for the acid components HY to be identical or different and any desired sequence of the addition of different acid components HY to be used, and the salts obtained are optionally further purified by crystallisation.

公开(公告)号：HU219587B

公开(公告)日：2001-05-28

申请号：HU9300374

申请日：1993-02-12

Applicant: HOECHST AG

Inventor： DEFOSSA ELISABETH ,  FISCHER GERD ,  GERLACH UWE ,  HOERLEIN ROLF ,  KRASS NORBERT ,  LATTRELL RUDOLF ,  STACHE ULRICH ,  WOLLMANN THEODOR

IPC: A61K31/545 ,  A61K31/546 ,  A61P31/04 ,  C07D277/20 ,  C07D277/40 ,  C07D417/12 ,  C07D501/00 ,  C07D501/04 ,  C07D501/06 ,  C07D501/34 ,  C07D501/26

Abstract: The invention relates to a process for the preparation of cephem prodrug esters of the formula in which R is C1-C5-alkanoyloxy-C1-C3-alkyl or C1-C5-alkoxycarbonyloxy-C1-C3-alkyl and X is an inorganic or organic anion, and in which the hydroxyimino group is present in the syn form, characterised in that a compound of the formula II in which R is a protective group which can be eliminated by acid hydrolysis, is reacted with a bis(2-benzothiazolyl) disulphide of the formula VI in which R is hydrogen, C1-C6-alkyl, C2-C6-alkenyl, C3-C6-alkynyl, C1-C6-alkyloxy, C2-C6-alkenyloxy, C3-C6-alkynyloxy, hydroxyl, acetoxy, halogen, nitro, amino, carboxyl or the sulpho group, and triphenylphosphine in an inert solvent in the presence of a tertiary amine to give a compound of the formula V in which R and R have the abovementioned meanings, subsequently this compound is reacted with a 7-aminoceph-3-em-4-carboxylic ester of the formula III in which R has the abovementioned meaning, in inert organic or dipolar aprotic solvents at temperatures between 0 DEG C and +80 DEG C, and the oxime-protected compound of the formula IV which is formed in which R and R have the abovementioned meanings, and in which the protected oxime group is present in the syn form, is treated with inorganic acids or with aliphatic or aromatic sulphonic acids in organic solvents at temperatures between +20 DEG and +110 DEG C to form the compound of the formula I.

公开(公告)号：HK1012017A1

公开(公告)日：1999-07-23

申请号：HK98113243

申请日：1998-12-12

Applicant: HOECHST AG

Inventor： LATTRELL RUDOLF ,  WOLLMANN THEODOR ,  WALLMEIER HOLGER ,  HAMMANN PETER ,  ISERT DIETER

IPC: A61K38/08 ,  A61K38/12 ,  A61K38/00 ,  A61P31/00 ,  A61P31/04 ,  C07K7/06 ,  C07K7/56 ,  C07K7/60 ,  C07K14/195 ,  C07K14/41 ,  C07K ,  A61K

Abstract: Lipopeptide derivatives of the formula I I with R1 equal to OH or NH2 and R2 a C8-C22-acyl radical, pharmaceutical products which are effective for bacterial infections and contain such lipopeptide derivatives, process for preparing the lipopeptide derivatives and the pharmaceutical products, and the use of the lipopeptide derivatives for controlling bacterial infections are described.

公开(公告)号：SK279013B6

公开(公告)日：1998-05-06

申请号：SK276192

申请日：1992-09-04

Applicant: HOECHST AG

Inventor： FISCHER GERD ,  DEFOSSA ELISABETH ,  GERLACH UWE ,  HORLEIN ROLF ,  KRASS NORBERT ,  LATTRELL RUDOLF ,  STACHE ULRICH ,  WOLLMANN THEODOR ,  ISERT DIETER

IPC: A61K31/545 ,  A61K31/546 ,  A61P31/04 ,  C07D501/00 ,  C07D501/06 ,  C07D501/34 ,  C07D501/56

Abstract: This patent describes diastereomer of 1-(isoproxycarbonyloxy)ethylester of (6R,7R)-7-[2-(2- -aminothiazol-4-yl)-2(Z)-methoxyimino)acetamido]-3- -(methoxymethyl)-3-cefem-4-carboxylic acid with a general formula (I), salts acceptable from physiological point of view, derived based on this compound and this diasteromer in form of pure salt, from diasteremeric point of view with a general formula (II), where HX is inorganic acid selected of the group including HCl, HBr, HI, HBF4, HNO3, HClO4, H2SO4, H3PO4 or organic acid selected of the group including aliphatic or aromatic sulphonic acids. This patent also describes a procedure related to the preparation of the above mentioned diastereomers or pure salts from diastereomeric point of view, together with a pharmaceutical composition containing these compounds and utilisation of the compound with a general formula (I) or (II), pure for diastereomeric point of view, to prepare medicaments for check and control of bacterial infections.

公开(公告)号：NO301982B1

公开(公告)日：1998-01-05

申请号：NO922023

申请日：1992-05-22

Applicant: HOECHST AG

Inventor： DEFOSSA ELISABETH ,  FISCHER GERD ,  JENDRALLA JOACHIM-HEINER ,  LATTRELL RUDOLF ,  WOLLMANN THEODOR ,  ISERT DIETER

IPC: A61K31/545 ,  A61K31/546 ,  A61P31/04 ,  C07B57/00 ,  C07D417/12 ,  C07D501/00 ,  C07D501/12 ,  C07D501/18 ,  C07D501/32 ,  C07D501/34

Abstract: The invention relates to crystalline acid addition salts of the two diastereomers of the 1-(2,2-dimethylpropionyloxy)ethyl ester of 3-cephem-4-carboxylic acid of the general formula II in which X represents the anion of a physiologically acceptable, mono- or polybasic, inorganic or organic acid and the group =N-OH is in the syn position, pharmaceutical preparations active against bacterial infections and which contain such cephem derivatives, a process for the preparation of the cephem derivatives, and the use of the cephem derivatives for the control of bacterial infections.

公开(公告)号：FI951468A

公开(公告)日：1995-10-01

申请号：FI951468

申请日：1995-03-28

Applicant: HOECHST AG

Inventor： LATTRELL RUDOLF ,  WOLLMANN THEODOR ,  WALLMEIER HOLGER ,  HAMMANN PETER ,  ISERT DIETER

IPC: A61K38/08 ,  A61K38/00 ,  A61K38/12 ,  A61P31/00 ,  A61P31/04 ,  C07K7/06 ,  C07K7/56 ,  C07K7/60 ,  C07K14/195 ,  C07K14/41 ,  C07K

Abstract: Lipopeptide derivatives of the formula I I with R1 equal to OH or NH2 and R2 a C8-C22-acyl radical, pharmaceutical products which are effective for bacterial infections and contain such lipopeptide derivatives, process for preparing the lipopeptide derivatives and the pharmaceutical products, and the use of the lipopeptide derivatives for controlling bacterial infections are described.

公开(公告)号：AU2218392A

公开(公告)日：1993-03-11

申请号：AU2218392

申请日：1992-09-08

Applicant: HOECHST AG

Inventor： FISCHER GERD ,  DEFOSSA ELISABETH ,  GERLACH UWE ,  HOERLEIN ROLF ,  KRASS NORBERT ,  LATTRELL RUDOLF ,  STACHE ULRICH ,  WOLLMANN THEODOR ,  ISERT DIETER

IPC: A61K31/545 ,  A61K31/546 ,  A61P31/04 ,  C07D501/00 ,  C07D501/06 ,  C07D501/34 ,  C07D501/56

Abstract: Enterally absorbable diastereomers of (6R,7R)-7-[2-(2-aminothiazol-4-yl)-2-(Z)-(methoxyimino)acetamido]-3-(m ethoxymethyl)-3-cephem-4-carboxylic acid 1-(isopropoxycarbonyloxy)ethyl ester of the formula I and its physiologically acceptable salts and also diastereomerically pure salts of the compounds of the general formula II where HX represents a mono- or polybasic acid and where X represents an inorganic or organic physiologically acceptable anion, and a process for the preparation of these compounds of the formula I or II are described, which is characterised in that on mixing together one equivalent of a solution of the diastereomer mixture of the formula III with 0.2 - 2 equivalents of a solution of the acid component HY the more poorly soluble diastereomer of the general formula IV is first precipitated and separated off by filtration, then the more readily soluble diastereomer of the general formula IV is precipitated from the filtration solution, it being possible in the subsequent subsidiary steps for the acid components HY to be identical or different and any desired sequence of the addition of different acid components HY to be used, and the salts obtained are optionally further purified by crystallisation.

公开(公告)号：CA2069200A1

公开(公告)日：1992-11-25

申请号：CA2069200

申请日：1992-05-22

Applicant: HOECHST AG

Inventor： DEFOSSA ELISABETH ,  FISCHER GERD ,  JENDRALLA JOACHIM-HEINER ,  LATTRELL RUDOLF ,  WOLLMANN THEODOR ,  ISERT DIETER

IPC: A61K31/545 ,  A61K31/546 ,  A61P31/04 ,  C07B57/00 ,  C07D417/12 ,  C07D501/00 ,  C07D501/12 ,  C07D501/18 ,  C07D501/32 ,  C07D501/34

Abstract: HOE 91/F 161 : Crystalline acid addition salts of diastereomerically pure 1-(2,2-dimethylpropionyloxy)-ethyl- 3-cephem-4-carboxylate The invention relates to crystalline acid addition salt of the two diastereomers of the 1-(2,2-dimethylpropionyl-oxy)-ethyl- 3-cephem-4-carboxylate of the general formula II x HX II in which X is the anion of a physiologically acceptable, mono- or polybasic, inorganic or organic acid and the group =N-OH is in the syn-position, pharmaceutical formulations which are active against bacterial infections and contain such cephem derivatives, processes for the preparation of the cephem derivatives and the use of the cephem derivatives for combating bacterial infections.